Pharma BD Deal Intelligence
Pfizer paid ~$340M for Idun in 2005, then sold the whole subsidiary back for essentially nominal consideration ($250K + a $1M note) in 2010 after failing to advance its lead apoptosis/caspase program — the asset (emricasan) went on to fail three separate Phase IIb liver-disease trials under its new owner, Conatus, confirming the science never panned out.
Full analysis, sources & comparables →Pfizer to acquire Idun Pharmaceuticals; lead asset IDN-6556 in Phase 2 for liver transplant patients and hepatitis C with data showing it is well tolerated and…
An in-process research and development charge of $0.3 billion relating to the pending acquisition of Idun Pharmaceutical, Inc.
Conatus Pharmaceuticals reacquired Pfizer's Idun subsidiary five years post-acquisition, signaling Pfizer deprioritized the apoptosis liver-disease platform.
Source summaries from our enrichment pipeline; follow links for originals.
All 6 sources with sentiment breakdown →
Pfizer completes acquisition of Idun Pharmaceuticals (apoptosis-focused biotech). Estimated $298M (some sources $400-500M); $250M IPR&D charge.
Pfizer paid ~$340M for Idun in 2005, then sold the whole subsidiary back for essentially nominal consideration ($250K + a $1M note) in 2010 after failing to advance its lead apoptosis/caspase program — the asset (emricasan) went on to fail three separate Phase IIb liver-disease trials under its new owner, Conatus, confirming the science never panned out.
Assessment window: 15yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Pfizer Inc. / Idun Pharmaceuticals, Inc. (this deal) | 2005 | $298M | 10 |
| Pfizer Inc. / BioNTech SE | 2020 | $748M | 100 |
| Pfizer Inc. / FoldRx Pharmaceuticals | 2010 | — | 99 |
| Pfizer Inc. / Medivation Inc. | 2016 | $14.0B | 86 |
| Pfizer Inc. / Wyeth | 2009 | $68.0B | 86 |
| Pfizer Inc. / Warner-Lambert Company | 2000 | $90.0B | 83 |
| Pfizer Inc. / Arvinas, Inc. | 2021 | $2.4B | 77 |
← Browse all deals · How we score deals
More: 2005 deals · Pfizer Inc. deals